



March 14, 2024

**BSE Limited**

Department of Corporate Services,  
P. J. Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**Mumbai - 400 051.**

*Dear Sir/Madam,*

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').**

Vide our letter dated October 16, 2023, we had informed the Stock Exchanges as regards the Company, having entered into a Business Transfer Agreement ('BTA') with Lupin Manufacturing Solutions Limited ('LMSL'), wholly owned subsidiary of the Company, to carve-out Active Pharmaceutical Ingredients manufacturing sites situate at Dabhasa and Visakhapatnam and select R&D operations, including fermentation, at Lupin Research Park, Pune.

We are now pleased to inform you that today i.e. March 14, 2024, the Company executed with LMSL, an amendment agreement to the BTA, to record pending minor post-closing adjustments and completed all formalities. Thus, the transaction has been completed.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS - 11973)**